Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 11/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.51 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30354925 | 1.00 | SYK (0.69) | SYKKDM4EGAAMAPTAURKB | |
| SCHEMBL1406446 | 0.85 | SYK (0.65) | SYKAURKBINCENPEGFRERBB2 | |
| SCHEMBL6190711 | 0.85 | SYK (0.69) | SYKAURKBINCENPEGFRERBB2 | |
| SCHEMBL30354815 | 0.84 | GAA (0.58) | SYKKDM4EGAAMAPTLMNA | |
| SCHEMBL30354819 | 0.84 | GAA (0.51) | SYKKDM4EGAAMAPTEGFR | |
| SCHEMBL26136200 | 0.84 | GAA (0.51) | SYKKDM4EGAAMAPTEGFR | |
| SCHEMBL1406672 | 0.82 | SYK (0.62) | SYKKDM4EAURKBINCENPSMN1; SMN2 | |
| SCHEMBL5569189 | 0.82 | MAPT (0.53) | SYKKDM4EGAAMAPTLMNA | |
| SCHEMBL30354884 | 0.82 | MAPT (0.53) | SYKKDM4EGAAMAPTLMNA | |
| SCHEMBL17601189 | 0.82 | SYK (1.00) | SYKMAPTAURKBINCENPEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278965-A1 | NOVEL CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS COMPRISING 2 OR MORE ARYL OR HETEROARYL CONNECTED VIA LINKER AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-09-07 | — | — | US | disclosed |
| EP-4169916-A1 | CARBONOHYDRAZONOYL DICYANIDE COMPOUND INCLUDING AT LEAST TWO TYPES OF ARYL OR HETEROARYL LINKED BY NOVEL LINKER, AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2023-04-26 | — | — | EP | disclosed |
| WO-2021256902-A1 | CARBONOHYDRAZONOYL DICYANIDE COMPOUND INCLUDING AT LEAST TWO TYPES OF ARYL OR HETEROARYL LINKED BY NOVEL LINKER, AND USE THEREOF | 한국과학기술연구원 | 2021-12-23 | — | — | WO | disclosed |
| EP-1838712-B8 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2011-10-12 | — | — | EP | disclosed |
| US-7947676-B2 | 2-{[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]oxy-}ethanol; erbB2 receptor tyrosine kinase inhibitor; anticarcinogenic, antitumor agnet; solid tumor and nonsolid such as leukaemia, multiple myeloma and lymphoma | ASTRAZENECA AB (SE) | 2011-05-24 | — | — | US | disclosed |
| EP-1838712-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| US-20080108613-A1 | Pyrazolopyrimidine Compounds as Antitumor Agents | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
| EP-1838712-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| WO-2006064196-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| EP-1664028-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026151-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278965-A1 | NOVEL CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS COMPRISING 2 OR MORE ARYL OR HETEROARYL CONNECTED VIA LINKER AND USE THEREOF | AADAC, CBR3, MTCL3 | SYK 1963/4885KDM4E 2383/4885GAA 3465/4885 |
| US-20080108613-A1 | Pyrazolopyrimidine Compounds as Antitumor Agents | ERBB2, ERBB3, ERBB4 | SYK 218/4885KDM4E 3375/4885GAA 2156/4885 |
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ABL1, ERBB2, LCK | SYK 118/4885KDM4E 3043/4885GAA 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.